<?xml version="1.0" encoding="UTF-8"?>
<ref id="B89-pharmaceuticals-12-00060">
 <label>89.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Cai</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Sun</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Song</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Xu</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Bei</surname>
    <given-names>Z.</given-names>
   </name>
   <name>
    <surname>Zhang</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Dou</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>H.</given-names>
   </name>
  </person-group>
  <article-title>Viral polymerase inhibitors T-705 and T-1105 are potential inhibitors of Zika virus replication</article-title>
  <source>Arch. Virol.</source>
  <year>2017</year>
  <volume>162</volume>
  <fpage>2847</fpage>
  <lpage>2853</lpage>
  <pub-id pub-id-type="doi">10.1007/s00705-017-3436-8</pub-id>
  <pub-id pub-id-type="pmid">28597088</pub-id>
 </element-citation>
</ref>
